Compass Therapeutics CEO Vered Bisker-Leib resigns; Thomas Schuetz appointed CEO

Compass Therapeutics, Inc.

Vered Bisker-Leib, PhD, MBA resigned as CEO and board member effective May 28, 2024, not due to any disagreement.
Thomas Schuetz, MD, PhD (President of R&D, Vice Chair) appointed President and CEO, and Principal Executive/Financial/Accounting Officer.
Separation agreement: 18 months base salary, up to 18 months COBRA reimbursement, release of claims.
Consulting agreement: 15 months at $45,000 annual fee; outstanding equity continues vesting during consultancy.
Schuetz previously served as CEO; returns to role; Board of Directors reduced to seven members.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Thomas Schuetz

President and Chief Executive Officer

CMPX · Compass Therapeutics, Inc.

Effective: 2024-05-28
Filed: May 28, 2024, 7:59 PM ET

On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.

Departed

Vered Bisker-Leib

Chief Executive Officer

CMPX · Compass Therapeutics, Inc.

Effective: 2024-05-28
Successor: Thomas Schuetz
Filed: May 28, 2024, 7:59 PM ET

On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Schuetz was appointed as President and Chief Executive Officer at Compass Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Vered Bisker-Leib resigned as Chief Executive Officer at Compass Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-003129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.